var data={"title":"Bedaquiline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bedaquiline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/533190?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bedaquiline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bedaquiline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15861179\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">An increased risk of death was seen in the bedaquiline treatment group (9/79, 11.4%) compared with the placebo treatment group (2/81, 2.5%) in 1 placebo-controlled trial. Only use bedaquiline when an effective treatment regimen cannot otherwise be provided.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">QT prolongation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">QT prolongation can occur with bedaquiline. Use with drugs that prolong the QT interval may cause additive QT prolongation. Monitor ECGs. Discontinue bedaquiline if significant ventricular arrhythmia or QTcF interval prolongation &gt;500 ms develops.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452832\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sirturo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15860479\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitubercular Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887643\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use with &ge;3 drugs also active against the patient's <i>M. tuberculosis</i> isolate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis (multidrug-resistant), pulmonary:</b> Oral: Directly observed therapy (DOT):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weeks 1 to 2: 400 mg once daily. <b>Note:</b> If a dose is missed during weeks 1 to 2, do not make up the missed dose, and continue the usual dosing schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weeks 3 to 24: 200 mg 3 times weekly (total weekly dose: 600 mg). <b>Note:</b> Space doses at least 48 hours apart. If a dose is missed during weeks 3 to 24, administer the missed dose as soon as possible, and resume the 3-times-weekly schedule.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887644\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887640\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate renal impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe renal impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor for adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) or peritoneal dialysis (PD): There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor for adverse reactions. Bedaquiline is highly protein bound and not likely to be removed by dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887641\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution and monitor for adverse reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452833\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sirturo: 100 mg [contains corn starch]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887598\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15878132\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM333729.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WvFvY7GRYkqsjJCb2asLbDw==&amp;TOPIC_ID=87509\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM333729.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887645\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally with food; swallow tablets whole. During weeks 3 to 24 of therapy, space doses at least 48 hours apart. Administer by directly observed therapy (DOT).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15860481\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis (multidrug-resistant), pulmonary:</b> Treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in combination therapy in adults (&ge;18 years of age) when an effective treatment regimen cannot otherwise be provided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not for use in extrapulmonary TB, latent infection due to TB, drug-sensitive TB, or treatment of other mycobacteria. Clinical data in HIV-1 infected patients coinfected with MDR-TB are limited (safety and efficacy has not been established).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15883728\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (38%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hemoptysis (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (9%), increased serum amylase (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hepatotoxicity, prolonged Q-T interval on ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887604\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887605\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: <b>[US Boxed Warning]: May prolong QTc interval. Use with drugs that prolong the QTc interval may cause additive prolongation. Monitor ECGs</b> at baseline, and at least 2, 12, and 24 weeks of treatment. Monitor ECG frequently with concurrent administration of other medications known to prolong the QTc interval (including fluoroquinolones, macrolide antibiotics or clofazimine) or in patients with a history of torsades de pointes, congenital long QT syndrome, uncompensated heart failure, low serum calcium, magnesium, or potassium levels, or a history of or ongoing bradyarrhythmias or hypothyroidism. Baseline potassium, calcium, and magnesium should be obtained and corrected, if abnormal. Also evaluate serum electrolytes if QT prolongation is detected during therapy. <b>Discontinue therapy (and all other QT prolonging drugs) if patient develops confirmed QTcF interval of &gt;500 ms</b> (confirmed by repeat ECG) or ventricular arrhythmia and monitor ECG to confirm return to baseline. If patient experiences syncope, obtain ECG to assess potential QTc prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased risk of hepatic reactions; avoid alcohol intake and other known hepatotoxic drugs, especially in patients with impaired hepatic function. Monitor AST, ALT, alkaline phosphatase, bilirubin, and symptoms of liver dysfunction (eg, fatigue, nausea, anorexia, jaundice, dark urine, liver tenderness, and hepatomegaly) at baseline and monthly during therapy, and as needed. Monitor more frequently if patient has underlying hepatic disease or is receiving concomitant drugs (CDC 2013). Test for viral hepatitis and discontinue other hepatotoxic medications if evidence of new or worsening hepatic disease occurs. Discontinue use if aminotransferase elevations are accompanied by total bilirubin elevation &gt;2 times ULN, aminotransferase elevations are &gt;8 times ULN, or aminotransferase elevations are &gt;5 times ULN and continue for &gt;2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased mortality: <b>[US Boxed Warning]: Increased risk of death was seen in the bedaquiline treatment group compared to the placebo treatment group in one placebo-controlled trial. Only use bedaquiline when an effective treatment regimen cannot otherwise be provided.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Administer by directly observed therapy (DOT). Should not be used for latent, extrapulmonary (eg, CNS) or drug-sensitive tuberculosis, or nontuberculosis mycobacteria. May be used for 24 weeks in adults with an isolate showing genotypic or phenotypic resistance to both isoniazid and rifampin when another effective treatment regimen cannot be used. Use for &gt;24 weeks should be evaluated on a case-by-case basis. Consider discontinuing bedaquiline 4 or 5 months before discontinuation of other drugs in the patient's regimen. Bedaquiline&rsquo;s long terminal half-life may predispose to acquired resistance if it is the sole antitubercular drug remaining in the patient's system. Safety and effectiveness has not been studied in children, HIV-1 infected persons, pregnant women, patients with extrapulmonary tuberculosis, or patients with comorbidities receiving other medications. When another effective treatment regimen cannot be used, bedaquiline may be evaluated for use on a case-by-case basis (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multidrug regimens (&ge;3 drugs) should be utilized against <i>M. tuberculosis</i> isolate; if failure/relapse occurs, have isolate tested <i>in vitro</i> for bedaquiline MIC. If <i>in vitro</i> susceptibility is not available, use with &ge;4 other drugs to which the patient's isolate is likely to be susceptible (CDC 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15976943\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C8 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15976941\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87509&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hepatotoxic effect of Bedaquiline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clofazimine: May enhance the QTc-prolonging effect of Bedaquiline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Bedaquiline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bedaquiline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bedaquiline. Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of Bedaquiline. Management: Consider alternatives to this combination. Concomitant use should only occur if the benefit of coadministration outweighs the risk. If combined, monitor for increased bedaquiline effects/toxicities (eg, QTc interval prolongation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May enhance the adverse/toxic effect of Bedaquiline. Rifabutin may decrease the serum concentration of Bedaquiline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887618\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with a standard meal (~22 g fat; 558 calories) increases bioavailability by approximately twofold. Management: Administer with food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887600\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887601\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887603\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bedaquiline is excreted into breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887648\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Susceptibility information for the background regimen against <i>M. tuberculosis </i>isolate should be obtained if possible. ECG should be obtained at baseline and at weeks 2, 12, and 24 during therapy. Monitor ECG weekly with concurrent administration of other medications known to prolong the QTc interval (including fluoroquinolones, macrolide antibiotics, or clofazimine) or if the patient has ongoing or a history of conditions predisposing them to QTc prolongation (torsade de pointes, congenital long QT syndrome, hypothyroidism, uncompensated heart failure, bradyarrhythmias) (CDC 2013). If QTc prolongation is detected during therapy, monitor ECG frequently to confirm QTc return to baseline. Baseline potassium, calcium, and magnesium should be obtained and corrected, if abnormal. Discontinue therapy (and all other QT prolonging drugs) if patient develops confirmed QTcF interval of &gt;500 ms (confirmed by repeat ECG) or ventricular arrhythmia.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor AST, ALT, alkaline phosphatase, and bilirubin at baseline, monthly during treatment, and as needed. Monitor more frequently if patient has underlying hepatic disease or is receiving concomitant hepatotoxic drugs (CDC 2013). Further evaluate patients with evidence of liver dysfunction (AST/ALT and/or bilirubin elevations, and/or symptoms [eg fatigue, nausea, anorexia, hepatomegaly]). Discontinue if AST or ALT elevations are &gt;5 times ULN and persist &gt;2 weeks, are &gt;8 times ULN, or if elevations also include total bilirubin &gt;2 times ULN.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor weekly for arthralgias, chest pain, headache, hemoptysis, nausea, and rash. Monitoring serum bedaquiline levels may be considered in patients with renal impairment. Sputum specimens should be evaluated monthly throughout treatment and at the end of treatment, even if cultures become negative. Specimens positive for <i>M. tuberculosis</i> (including pretreatment specimen) should be evaluated further by a laboratory (in conjunction with a state public health laboratory) that performs bedaquiline resistance testing (CDC 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887621\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a diarylquinoline antimycobacterial, inhibits the proton transfer chain of mycobacterial ATP synthase required for energy generation in <i>M. tuberculosis</i>.  It is not active against human ATP synthase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15887623\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Significantly increased with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~164 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99.9%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4; forms N-monodesmethyl metabolite (M2) which has 4 to 6 times less antimycobacterial potency than parent drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: ~5.5 months (bedaquiline and M2 metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces; urine (&le;0.001%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20958162\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sirturo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (188): $36,000.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24170891\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sirturo (AT, BB, BE, CZ, DE, DK, EE, ES, FR, GB, HR, HU, IE, KR, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. <i>MMWR Recomm Rep</i>. 2013;62(RR-09):1-12.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003, <i>MMWR Recomm Rep</i>, 52(RR-11):3-5. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diacon AH, Donald PR, Pym A, et al, &ldquo;Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance,&rdquo; <i>Antimicrob Agents Chemother</i>, 2012, 56(6):3271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/22391540/pubmed\" target=\"_blank\" id=\"22391540\">22391540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al, &ldquo;14-Day Bactericidal Activity of PA-824, Bedaquiline, Pyrazinamide and Moxifloxacin Combinations: A Randomised Trial,&rdquo; <i>Lancet</i>, 2012, 380(9846):986-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/22828481/pubmed\" target=\"_blank\" id=\"22828481\">22828481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diacon AH, Pym A, Grobusch M, et al, &ldquo;The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis,&rdquo; <i>N Engl J Med</i>, 2009, 360(23):2397-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/19494215/pubmed\" target=\"_blank\" id=\"19494215\">19494215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dooley KE, Park JG, Swindells S, et al, &ldquo;Safety, Tolerability and Pharmacokinetic Interaction of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267,&rdquo; <i>J Acquir Immune Defic Syndr</i>, 2012, 59(5):455-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/22126739/pubmed\" target=\"_blank\" id=\"22126739\">22126739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rustomjee R, Diacon AH, Allen J, et al, &ldquo;Early Bactericidal Activity and Pharmacokinetics of Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis,&rdquo; <i>Antimicrob Agents Chemother</i>, 2008, 52(8):2831-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/18505852/pubmed\" target=\"_blank\" id=\"18505852\">18505852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sirturo (bedaquiline) [prescribing information]. Titusville, NJ: Janssen Therapeutics; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Villemagne B, Crauste C, Flipo M, et al, &ldquo;Tuberculosis: The Drug Development Pipeline at a Glance,&rdquo; <i>Eur J Med Chem</i>, 2012, 51:1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bedaquiline-drug-information/abstract-text/22421275/pubmed\" target=\"_blank\" id=\"22421275\">22421275</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87509 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F15861179\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452832\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15860479\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15887643\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15887644\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15887640\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15887641\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20452833\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15887598\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15878132\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15887645\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15860481\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15883728\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15887604\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15887605\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15976943\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15976941\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F15887618\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F15887600\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15887601\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15887603\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15887648\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15887621\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15887623\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F20958162\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24170891\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87509|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bedaquiline-patient-drug-information\" class=\"drug drug_patient\">Bedaquiline: Patient drug information</a></li></ul></div></div>","javascript":null}